p53 mutations and overexpression in locally advanced breast cancers.

por Faille, A., De Cremoux, P., Extra, J. M., Linares, G., Espie, M., Bourstyn, E., De Rocquancourt, A., Giacchetti, S., Marty, M., Calvo, F.
Publicado 1994

Prognostic value of persistent node involvement after neoadjuvant chemotherapy in patients with operable breast cancer

por Pierga, J-Y, Mouret, E, Diéras, V, Laurence, V, Beuzeboc, P, Dorval, T, Palangié, T, Jouve, M, Vincent-Salomon, A, Scholl, S, Extra, J-M, Asselain, B, Pouillart, P
Publicado 2000

High-dose sequential epirubicin and cyclophosphamide with peripheral blood stem cell support for advanced breast cancer: results of a phase II study

por Cottu, P H, Extra, J M, Espie, M, Marolleau, J P, Roquancourt, A de, Makke, J, Miclea, J M, Laurence, V, Mayeur, D, Lerebours, F, Cuvier, C, Marty, M
Publicado 2001

Long-term survival of advanced triple-negative breast cancers with a dose-intense cyclophosphamide/anthracycline neoadjuvant regimen

por Giacchetti, S, Porcher, R, Lehmann-Che, J, Hamy, A-S, de Roquancourt, A, Cuvier, C, Cottu, P-H, Bertheau, P, Albiter, M, Bouhidel, F, Coussy, F, Extra, J-M, Marty, M, de Thé, H, Espié, M
Publicado 2014

Immunohistochemical subtypes predict the clinical outcome in high-risk node-negative breast cancer patients treated with adjuvant FEC regimen: results of a single-center retrospect...

por Rahal, S., Boher, J M, Extra, J M, Tarpin, C., Charafe-Jauffret, E., Lambaudie, E., Sabatier, R., Thomassin-Piana, J., Tallet, A., Resbeut, M., Houvenaeghel, G., Laborde, L., Bertucci, F., Viens, P., Gonçalves, A.
Publicado 2015